Effects of exogenous vasoactive intestinal peptide on mesenteric lymph pathway during early intestinal ischemia-reperfusion injury in rats

Regulatory Peptides

Volumn 186, Issue , 2013, Pages 36-42

  Yang, Hui ^a   Jin, Yu ^a   Wang, Chun H ^b   Tang, Cheng W ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Intestinal injury; Ischemia reperfusion; Lymph flow; Lymphocyte trafficking; VIP

Indexed keywords

CHROMIUM 51; ENDOTOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VIP 28;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNULATION; CELL LABELING; CONTROLLED STUDY; DRUG MECHANISM; IN VIVO STUDY; INTESTINE INJURY; INTESTINE ISCHEMIA; LARGE INTESTINE; LYMPH FLOW; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOID TISSUE; MALE; MESENTERY LYMPH NODE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STOMACH; TISSUE SECTION;

INTESTINAL INJURY; ISCHEMIA-REPERFUSION; LYMPH FLOW; LYMPHOCYTE TRAFFICKING; VIP;

ANIMALS; CELL MOVEMENT; DRUG EVALUATION, PRECLINICAL; ENDOTOXINS; ILEUM; LYMPH; LYMPHATIC VESSELS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MESENTERIC ARTERIES; MESENTERIC VASCULAR OCCLUSION; RATS; RATS, WISTAR; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84881309583     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.06.014     Document Type: Article

References (41)

1. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activatingpolypeptide. Pharmacol Rev 1998, 50:265-270. [PubMed: 9647867].
2. Bryant M.G., Polak M.M., Modlin I., Bloom S.R., Albuquerque R.H., Pearse A.G. Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet 1976, 1:991-993. [PubMed: 57443].
3. Gutiérrez-Cañas I., Juarranz Y., Santiago B., Martínez C., Gomariz R.P., Pablos J.L., Leceta J. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008, 22:312-317. [PubMed: 17951026].
4. Delgado M., Pozo D., Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004, 56:249-290. [PubMed: 15169929].
5. Gonzalez-Rey E., Anderson P., Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis 2007, 66(Suppl. 3):70-76. [PubMed: 17934101].
6. Maggi C.A., Giachetti A., Dey R.D., Said S.I. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995, 75:277-322. [PubMed: 7724664].
7. Smalley S.G.R., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 2009, 157:225-234. [PubMed: 19604262].
8. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukocyte Biol 1998, 63:591-601. [PubMed: 9581803].
9. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-a production by Macrophages: in vitro and in vivo studies. J Immunol 1999, 162:2358-2367. [PubMed: 9973516].
10. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol 1996, 6:61-74. [PubMed: 8790782].
11. Leister I., Sydow J., Stojanovic T., Füzesi L., Sattler B., Heuser M., Becker H., Markus P.M. Impact of vasoactive intestinal polypeptide and gastrin-releasing peptide on small bowel microcirculation and mucosal injury after hepatic ischemia/reperfusion in rats. Int J Colorectal Dis 2005, 20:42-48. [PubMed: 15602648].
12. Leister I., Mbachu E.M., Post S., Samel S.T., Stojanovic T., Gutt C.N., Becker H., Markus P.M. Vasoactive intestinal polypeptide and gastrin-releasing peptide attenuate hepatic microvasculatory disturbances following intestinal ischemia and reperfusion. Digestion 2002, 66:186-192. [PubMed: 12481165].
13. Jungraithmayr W., De Meester I., Matheeussen V., Inci I., Augustyns K., Scharpé S., Weder W., Korom S. Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. Peptides 2010, 31:585-591. [PubMed: 20018218].
14. Clark J.A., Coopersmith C.M. Intestinal crosstalk-a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007, 28:384-393. [PubMed: 17577136].
15. Leaphart C.L., Tepas J.J. The gut is a motor of organ system dysfunction. Surgery 2007, 141:563-569. [PubMed: 17462455].
16. Chen Y., Lui V.C., Rooijen N.V., Tam P.K. Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut. Gut 2004, 53:1772-1780. [PubMed: 15542513].
17. Homer-Vanniasinkam S., Crinnion J.N., Gough M.J. Post-ischaemic organ dysfunction: a review. Eur J Vasc Endovasc Surg 1997, 14:195-203. [PubMed: 9345239].
18. Fanous M.Y.Z., Phillips A.J., Windsor J.A. Mesenteric lymph: the bridge to future management of critical illness. J Pancreas 2007, 8:374-399. [PubMed: 17625290].
19. Diepenhorst G.M.P., van Gulik T.M., Hack C.E. Complement-mediated ischemia-reperfusion injury. Lesson learned from animal and clinical studies. Ann Surg 2009, 249:889-899. [PubMed: 19474697].
20. Deitch E.A. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. Ann N Y Acad Sci 2010, 1207(Suppl. 1):E103-E111. [PubMed: 20961300].
21. Deitch E.A., Xu D., Kaise V.L. Role of the gut in the development of injury- and shock induced SIRS and MODS: the gut-lymph hypothesis, a review. Front Biosci 2006, 11:520-528. [PubMed: 16146750].
22. Magnotti L.J., Upperman J.S., Xu D.Z., Lu Q., Deitch E.A. Gut-derived mesenteric lymph but not portal blood increases endothelial cell permeability and potentiates lung injury following hemorrhagic shock. Ann Surg 1998, 228:518-527. [PubMed: 9790341].
23. Xu B.H., Cook R.E., Michie S.A. α4β7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice. J Autoimmun 2010, 35:124-129. [PubMed: 29488663].
24. Clay C.C., Rodrigues D.S., Brignolo L.L., Spinner A., Tarara R.P., Plopper C.G., Leutenegger C.M., Esser U. Chemokine networks and in vivo T-lymphocyte trafficking in nonhuman primates. J Immunol Methods 2004, 293:23-42. [PubMed: 15541274].
25. Bollman J.L., Caim J.C., Grindlay J.H. Techniques for collection of lymph from liver, small intestine or thoracic duct of the rat. J Lab Clin Med 1948, 33:1349-1352. [PubMed: 18886337].
26. Hamann A. Lymphocyte migration in vivo: the mouse model, immunology methods manual, the comprehensive sourcebook of techniques. Mucosal immunology 1997, 1334-1515. Academic Press, San Diego. 2nd ed. P.L. Ogra, M.E. Lamm, J. Bienenstock (Eds.).
27. Herrera D.J., Morris K., Johnston C., Griffiths P. Automated assay for plasma D-lactate by enzymatic spectrophotometric analysis with sample blank correction. Ann Clin Biochem 2008, 45:177-183. [PubMed: 18325182].
28. Mallick A., Bodenham A.R. Disorders of the lymph circulation: their relevance to anaesthesia and intensive care. Br J Anaesth 2003, 91:265-272. [PubMed: 12878626].
29. Hassoun H.T., Kone B.C., Mercer D.W., Moody F.G., Weisbrodt N.W., Moore F.A. Post-injury multiple organ failure: the role of the gut. Shock 2001, 15:1-10. [PubMed: 11198350].
30. Yang H., Jin Y., Li M., Wang C.H., Tang C.W. Disturbances of mesenteric lymph flow and in vivo intestinal lymphocyte trafficking during early gut injury induced by ischemia-reperfusion in rats. Lymphology 2012, 45:130-139. [PubMed: 23342933].
31. Siegmund B., Sennello J.A., Jones-Carson J., Gamboni-Robertson F., Lehr H.A., Batra A., Fedke I., Zeitz M., Fantuzzi G. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut 2004, 53:965-972. [PubMed: 15194645].
32. Tang C., Lan C., Wang C., Liu R. Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells. Shock 2005, 23:470-475. [PubMed: 15834315].
33. Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., Brabet P., Leceta J., Gomariz R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 2002, 99:1053-1058. [PubMed: 11792830].
34. Gomariz R.P., Arranz A., Abad C., Torroba M., Martinez C., Rosignoli F., Garcia-Gómez M., Leceta J., Juarranz Y. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 2005, 78:491-502.
35. Said S.I., Dickman K.G. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept 2000, 93:21-29. [PubMed: 11033049].
36. Sambol J.T., White J., Horton J.W., Deitch E.A. Burn-induced impairment of cardiac contractile function is due to gut-derived factors transported in mesenteric lymph. Shock 2002, 18:272-276. [PubMed:12353930].
37. Lee M.A., Yatani A., Sambol J.T., Deitch E.A. Role of gut-lymph factors in the induction of burn-induced and trauma-shock-induced acute heart failure. Int J Clin Exp Med 2008, 1:171-180. [PubMed: 19079671].
38. Murch O., Abdelrahman M., Kapoor A., Thiemermann C. Muramyl dipeptide enhances the response to endotoxin to cause multiple organ injury in the anesthetized rat. Shock 2008, 29:388-394. [PubMed: 17693945].
39. Cavriani G., Domingos H.V., Oliveira-Filho R.M., Sudo-Hayashi L.S., Vargaftig B.B., de Lima W.T. Lymphatic thoracic duct ligation modulates the serum levels of IL-1beta and IL-10 after intestinal ischemia/reperfusion in rats with the involvement of tumor necrosis factor alpha and nitric oxide. Shock 2007, 27:209-213. [PubMed: 17224798].
40. Shigematsu T., Wolf R.E. Granger DN.T-lymphocytes modulate the microvascular and inflammatory responses to intestinal ischemia-reperfusion. Microcirculation 2002, 9:99-109.
41. Fukatsu K., Sakamoto S., Hara E., Ueno C., Maeshima Y., Matsumoto I., Mochizuki H., Hiraide H. Gut ischemia-reperfusion affects gut mucosal immunity: a possible mechanism for infectious complications after severe surgical insults. Crit Care Med 2006, 34:182-187. [PubMed: 16374173].